Charles River Laboratories International (CRL) EBIAT (2016 - 2025)
Historic EBIAT for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $55.6 million.
- Charles River Laboratories International's EBIAT fell 2096.74% to $55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year decrease of 11860.32%. This contributed to the annual value of $25.3 million for FY2024, which is 9473.51% down from last year.
- Per Charles River Laboratories International's latest filing, its EBIAT stood at $55.6 million for Q3 2025, which was down 2096.74% from $52.7 million recorded in Q2 2025.
- Charles River Laboratories International's EBIAT's 5-year high stood at $189.1 million during Q4 2022, with a 5-year trough of -$213.7 million in Q4 2024.
- Over the past 5 years, Charles River Laboratories International's median EBIAT value was $94.3 million (recorded in 2024), while the average stood at $80.6 million.
- Per our database at Business Quant, Charles River Laboratories International's EBIAT soared by 4894.19% in 2022 and then crashed by 21312.24% in 2024.
- Over the past 5 years, Charles River Laboratories International's EBIAT (Quarter) stood at $139.8 million in 2021, then surged by 35.24% to $189.1 million in 2022, then dropped by 0.08% to $189.0 million in 2023, then crashed by 213.12% to -$213.7 million in 2024, then skyrocketed by 125.99% to $55.6 million in 2025.
- Its EBIAT stands at $55.6 million for Q3 2025, versus $52.7 million for Q2 2025 and $25.9 million for Q1 2025.